Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial

被引：0
|
作者：
Ashina, M. [1 ]
Tepper, S. J. [2 ]
Reuter, U. [3 ]
Blumenfeld, A. M. [4 ]
Hutchinson, S. [5 ]
Xia, J. [6 ]
Miceli, R. [6 ]
Severt, L. [6 ]
Finnegan, M. [6 ]
Trugman, J. M. [6 ]
机构：
[1] Univ Copenhagen, Danish Headache Ctr, Glostrup, Denmark
[2] Geisel Sch Med Dartmouth, Hanover, NH USA
[3] Charite, Berlin, Germany
[4] Headache Ctr Southern Calif, Carlsbad, CA USA
[5] Orange Cty Migraine & Headache Ctr, Irvine, CA USA
[6] AbbVie, Madison, NJ USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0301
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [41] ADHD treatment with once-daily OROS methylphenidate: Final results from a long-term open-label study
    Wilens, T
    McBurnett, K
    Stein, M
    Lerner, M
    Spencer, T
    Wolraich, M
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2005, 44 (10): : 1015 - 1023
  • [42] Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized Controlled Trial and Open-Label Extension Study
    Keystone, Edward
    Landewe, Robert
    van Vollenhoven, Ronald
    Combe, Bernard
    Strand, Vibeke
    Mease, Phillip
    Shaughnessy, Laura
    VanLunen, Brenda
    van der Heijde, Desiree
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1455 - 1456
  • [43] LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: 5-YEAR RESULTS FROM A 52-WEEK RANDOMIZED CONTROLLED TRIAL AND OPEN-LABEL EXTENSION STUDY
    Keystone, Edward
    Landewe, Robert
    van Vollenhoven, Ronald
    Combe, Bernard
    Strand, Vibeke
    Mease, Philip J.
    Shaughnessy, Laura
    vanlunen, Brenda
    van der Heijde, Desiree
    RHEUMATOLOGY, 2014, 53 : 96 - 96
  • [44] Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study
    Keystone, Edward
    Landewe, Robert
    van Vollenhoven, Ronald
    Combe, Bernard
    Strand, Vibeke
    Mease, Philip J.
    Shaughnessy, Laura
    VanLunen, Brenda
    van der Heijde, Desiree
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S596 - S597
  • [45] Long-term efficacy and safety of aripiprazole vs. olanzapine in schizophrenia:: a 52-week, open-label extension study
    Ebrecht, M
    Modell, S
    Werner, C
    Spevakné-Göröcs, T
    Kungel, M
    PHARMACOPSYCHIATRY, 2005, 38 (05) : 238 - 238
  • [46] Long-Term Safety and Efficacy of Donepezil in Patients with Severe Alzheimer's Disease: Results from a 52-Week, Open-Label, Multicenter, Extension Study in Japan
    Homma, Akira
    Imai, Yukimichi
    Tago, Hisao
    Asada, Takashi
    Shigeta, Masahiro
    Iwamoto, Toshihiko
    Takita, Masashi
    Arimoto, Itaru
    Koma, Hiroshi
    Takase, Takao
    Ohbayashi, Toshio
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2009, 27 (03) : 232 - 239
  • [47] Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine
    Ashina, Messoud
    Tepper, Stewart
    Reuter, Uwe
    Blumenfeld, Andrew
    Hutchinson, Susan
    Xia, Jing
    Miceli, Rosa
    Severt, Lawrence
    Finnegan, Michelle
    Trugman, Joel
    NEUROLOGY, 2021, 96 (15)
  • [48] Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine
    Ashina, M.
    Tepper, S. J.
    Reuter, U.
    Blumenfeld, A. M.
    Hutchinson, S.
    Xia, J.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 46 - 46
  • [49] Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
    Jacobsen, Paula L.
    Harper, Linda
    Chrones, Lambros
    Chan, Serena
    Mahableshwarkar, Atul R.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2015, 30 (05) : 255 - 264
  • [50] Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 52-week, open-label extension studies
    Eerdekens, M.
    Kramer, M.
    Martinez, L.
    Lane, R.
    Lim, P.
    Canuso, C.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 429 - 429
12345